The Prognostic and Predictive Value of EGFR and HER-2 in Advanced Non-small Cell Lung Cancer Patients Who Are Treated with Cisplatin and Paclitaxel.
- Author:
Jinyoung YOO
1
;
Byoung Yong SHIM
;
Seok Jin KANG
Author Information
- Publication Type:Original Article
- Keywords: Non-small cell lung carcinoma; Epidermal growth factor receptor; HER-2; Chromogenic in situ hybridization
- MeSH: Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Therapy, Combination; Genes, erbB-2; Humans; In Situ Hybridization; Paclitaxel; Receptor, Epidermal Growth Factor
- From:Journal of Lung Cancer 2009;8(1):13-20
- CountryRepublic of Korea
- Language:Korean
- Abstract: PURPOSE: Although both platinum-based drugs and third-generation drugs are commonly used as first-line therapy for patients with advanced, unresectable non-small cell lung cancer, their effectiveness and clinical outcomes vary. We investigated whether epidermal growth factor receptor (EGFR) and HER-2 were correlated with the chemoresponse and survival after treatment with a cisplatin plus paclitaxel regimen. MATERIALS AND METHODS: Forty-nine tumors were analyzed by chromogenic in situ hybridization (CISH) for EGFR and HER-2 gene amplification. RESULTS: Twenty-eight patients (57%) achieved a partial response (PR), 13 (27%) showed stable disease (SD) and 8 (16%) had progressive disease (PD). EGFR and HER-2 amplification was identified in 43% and 57% of the tumors, respectively. EGFR amplification revealed no association with either a chemoresponse or survival, whereas HER-2 was amplified more frequently in the patients with PD (88% vs. 54%, respectively, p=0.06) and in the patients with shorter survival (12 months vs. 20 months respectively, p=0.027). CONCLUSION: The evaluation of HER-2 gene amplification is a promising approach for identifying those patients who are most likely to benefit from combination chemotherapy with cisplatin and paclitaxel
